Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Apr;69(4):648–654. doi: 10.1038/bjc.1994.126

Enhancement of cyclophosphamide cytotoxicity in vivo by the benzamide analogue pyrazinamide.

M R Horsman 1, D J Chaplin 1
PMCID: PMC1968828  PMID: 8142253

Abstract

The ability of pyrazinamide to enhance the in vivo cytotoxicity of cyclophosphamide in Lewis lung and RIF-1 tumours was investigated. Using an in vivo/in vitro excision assay a large single dose of pyrazinamide (500 mg kg-1 i.p.) was shown to enhance the tumour cell killing by cyclophosphamide. This enhancement was greatest when pyrazinamide was administered before the alkylating agent and had a dose-modifying effect on all cyclophosphamide doses tested, giving rise to a mean (+/- 1 s.e.) enhancement ratio (ER) of 1.54 (+/- 0.15) for the Lewis lung and 1.24 (+/- 0.08) for the RIF-1 tumour. Pyrazinamide also increased the cytotoxic action of cyclophosphamide in a normal tissue, namely white blood cell counts. However, the ER was only 1.14 (+/- 0.08), which although not significantly different from the value seen in RIF-1 was significantly less than the ER obtained with Lewis lung, suggesting the possibility of a therapeutic gain. This benzamide analogue did not appear to inhibit recovery from cyclophosphamide-induced potentially lethal damage in tumours, nor did it alter the bioactivation of cyclophosphamide or the subsequent clearance of the cytotoxic species from the plasma, so the mechanism for this chemosensitisation remains unclear.

Full text

PDF
648

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ben-Hur E., Chen C. C., Elkind M. M. Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res. 1985 May;45(5):2123–2127. [PubMed] [Google Scholar]
  2. Boorstein R. J., Pardee A. B. 3-Aminobenzamide is lethal to MMS-damaged human fibroblasts primarily during S phase. J Cell Physiol. 1984 Sep;120(3):345–353. doi: 10.1002/jcp.1041200313. [DOI] [PubMed] [Google Scholar]
  3. Brown D. M., Horsman M. R., Hirst D. G., Brown J. M. Enhancement of melphalan cytotoxicity in vivo and in vitro by inhibitors of poly (ADP-ribose) polymerase. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1665–1668. doi: 10.1016/0360-3016(84)90524-8. [DOI] [PubMed] [Google Scholar]
  4. Brown J. M., Lemmon M. J., Horsman M. R., Lee W. W. Structure-activity relationships for tumour radiosensitization by analogues of nicotinamide and benzamide. Int J Radiat Biol. 1991 Mar;59(3):739–748. doi: 10.1080/09553009114550651. [DOI] [PubMed] [Google Scholar]
  5. Calcutt G., Ting S. M., Preece A. V. Tissue NAD levels and the response to irradiation of cytotoxic drugs. Br J Cancer. 1970 Jun;24(2):380–388. doi: 10.1038/bjc.1970.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chaplin D. J., Acker B., Olive P. L. Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1131–1135. doi: 10.1016/0360-3016(89)90267-8. [DOI] [PubMed] [Google Scholar]
  7. Chaplin D. J., Durand R. E., Olive P. L. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1279–1282. doi: 10.1016/0360-3016(86)90153-7. [DOI] [PubMed] [Google Scholar]
  8. Chaplin D. J., Horsman M. R., Trotter M. J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst. 1990 Apr 18;82(8):672–676. doi: 10.1093/jnci/82.8.672. [DOI] [PubMed] [Google Scholar]
  9. Chaplin D. J., Sheldon P. W., Stratford I. J., Ahmed I., Adams G. E. Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles. Int J Radiat Biol Relat Stud Phys Chem Med. 1983 Oct;44(4):387–398. doi: 10.1080/09553008314551331. [DOI] [PubMed] [Google Scholar]
  10. Chaplin D. J., Trotter M. J., Skov K. A., Horsman M. R. Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide. Br J Cancer. 1990 Oct;62(4):561–566. doi: 10.1038/bjc.1990.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Courtenay V. D. A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse. Br J Cancer. 1976 Jul;34(1):39–45. doi: 10.1038/bjc.1976.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Durkacz B. W., Omidiji O., Gray D. A., Shall S. (ADP-ribose)n participates in DNA excision repair. Nature. 1980 Feb 7;283(5747):593–596. doi: 10.1038/283593a0. [DOI] [PubMed] [Google Scholar]
  13. Durrant L. G., Boyle J. M. Potentiation of cell killing by inhibitors of poly(ADP-ribose) polymerase in four rodent cell lines exposed to N-methyl-N-nitrosourea or UV light. Chem Biol Interact. 1982 Feb;38(3):325–338. doi: 10.1016/0009-2797(82)90062-x. [DOI] [PubMed] [Google Scholar]
  14. Horsman M. R., Brown D. M., Hirst D. G., Brown J. M. Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase. Br J Cancer. 1986 Feb;53(2):247–254. doi: 10.1038/bjc.1986.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Horsman M. R., Brown D. M., Lemmon M. J., Brown J. M., Lee W. W. Preferential tumor radiosensitization by analogs of nicotinamide and benzamide. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1307–1310. doi: 10.1016/0360-3016(86)90160-4. [DOI] [PubMed] [Google Scholar]
  16. Horsman M. R., Brown J. M., Hirst V. K., Lemmon M. J., Wood P. J., Dunphy E. P., Overgaard J. Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):685–690. doi: 10.1016/0360-3016(88)90312-4. [DOI] [PubMed] [Google Scholar]
  17. Horsman M. R., Chaplin D. J., Brown J. M. Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res. 1989 Apr;118(1):139–150. [PubMed] [Google Scholar]
  18. Horsman M. R., Chaplin D. J., Overgaard J. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res. 1990 Dec 1;50(23):7430–7436. [PubMed] [Google Scholar]
  19. Horsman M. R., Evans J. W., Brown J. M. Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms. Br J Cancer. 1984 Sep;50(3):305–316. doi: 10.1038/bjc.1984.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Horsman M. R., Hansen P. V., Overgaard J. Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1273–1276. doi: 10.1016/0360-3016(89)90297-6. [DOI] [PubMed] [Google Scholar]
  21. Horsman M. R., Høyer M., Honess D. J., Dennis I. F., Overgaard J. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol. 1993 May;27(2):131–139. doi: 10.1016/0167-8140(93)90133-s. [DOI] [PubMed] [Google Scholar]
  22. Horsman M. R., Kristjansen P. E., Mizuno M., Christensen K. L., Chaplin D. J., Quistorff B., Overgaard J. Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice. Int J Radiat Oncol Biol Phys. 1992;22(3):451–454. doi: 10.1016/0360-3016(92)90851-8. [DOI] [PubMed] [Google Scholar]
  23. Jacobson E. L., Smith J. Y., Mingmuang M., Meadows R., Sims J. L., Jacobson M. K. Effect of nicotinamide analogues on recovery from DNA damage in C3H10T1/2 cells. Cancer Res. 1984 Jun;44(6):2485–2492. [PubMed] [Google Scholar]
  24. Jonsson G. G., Kjellén E., Pero R. W., Cameron R. Radiosensitization effects of nicotinamide on malignant and normal mouse tissue. Cancer Res. 1985 Aug;45(8):3609–3614. [PubMed] [Google Scholar]
  25. Kjellen E., Joiner M. C., Collier J. M., Johns H., Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol. 1991 Oct;22(2):81–91. doi: 10.1016/0167-8140(91)90002-x. [DOI] [PubMed] [Google Scholar]
  26. Law M. P., Hirst D. G., Brown J. M. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide. Br J Cancer. 1981 Aug;44(2):208–218. doi: 10.1038/bjc.1981.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lee I., Song C. W. The oxygenation of murine tumor isografts and human tumor xenografts by nicotinamide. Radiat Res. 1992 Apr;130(1):65–71. [PubMed] [Google Scholar]
  28. Nduka N., Skidmore C. J., Shall S. The enhancement of cytotoxicity of N-methyl-N-nitrosourea and of gamma-radiation by inhibitors of poly(ADP-ribose) polymerase. Eur J Biochem. 1980 Apr;105(3):525–530. doi: 10.1111/j.1432-1033.1980.tb04528.x. [DOI] [PubMed] [Google Scholar]
  29. Sakamoto H., Kawamitsu H., Miwa M., Terada M., Sugimura T. Enhancement of antitumor activity of bleomycin by benzamide in vitro and in vivo. J Antibiot (Tokyo) 1983 Mar;36(3):296–300. doi: 10.7164/antibiotics.36.296. [DOI] [PubMed] [Google Scholar]
  30. Smulson M. E., Schein P., Mullins D. W., Jr, Sudhakar S. A putative role for nicotinamide adenine dinucleotide-promoted nuclear protein modification in the antitumor activity of N-methyl-N-nitrosourea. Cancer Res. 1977 Sep;37(9):3006–3012. [PubMed] [Google Scholar]
  31. Stottmeier K. D., Beam R. E., Kubica G. P. The absorption and excretion of pyrazinamide. I. Preliminary study in laboratory animals and in man. Am Rev Respir Dis. 1968 Jul;98(1):70–74. doi: 10.1164/arrd.1968.98.1.70. [DOI] [PubMed] [Google Scholar]
  32. Tannock I., Guttman P. Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer. 1981 Feb;43(2):245–248. doi: 10.1038/bjc.1981.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Teicher B. A., Lazo J. S., Sartorelli A. C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 1981 Jan;41(1):73–81. [PubMed] [Google Scholar]
  34. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  35. Weiner I. M., Tinker J. P. Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention. J Pharmacol Exp Ther. 1972 Feb;180(2):411–434. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES